



Clinical trial results:

An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab in pediatric participants with mild to moderate COVID-19 at high risk of disease progression

Summary

EudraCT number	2021-003717-18
Trial protocol	GR
Global end of trial date	14 June 2023

Results information

Result version number	v1 (current)
This version publication date	30 December 2023
First version publication date	30 December 2023

Trial information

Trial identification

Sponsor protocol code	215226
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05124210
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS
Public contact	GSK Response Center, GlaxoSmithKline, +1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, +1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002899-PIP01-20
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 July 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	14 June 2023
Global end of trial reached?	Yes
Global end of trial date	14 June 2023
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To evaluate the pharmacokinetics by IV or IM administration of sotrovimab in children from birth to <18 years

To evaluate the safety and tolerability of sotrovimab by IV or IM administration

Protection of trial subjects:

Not Applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 December 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects**Subjects enrolled per country**

Country: Number of subjects enrolled	United States: 8
Worldwide total number of subjects	8
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	3
Adolescents (12-17 years)	5
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Total of 8 participants were enrolled in this study. Four age bands were planned to be enrolled (12 to less than 18 years, 6 to less than 12 years, 2 to less than 6 years and Birth to less than 2 years). Due to early termination of the study, no participants were enrolled in the 2 to less than 6 years and birth to less than 2 years age bands.

Pre-assignment

Screening details:

This study was conducted in 2 cohorts (Cohort A and Cohort B). The study was terminated due to decrease in in-vitro neutralization of sotrovimab against circulating Omicron BA.2 SARS-CoV-2 variants. Hence, Cohort B was not initiated. None of the participants received Intramuscular (IM) administration of sotrovimab.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)

Arm description:

Participants in the age group 6 to $<$ 12 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1

Arm type	Experimental
Investigational medicinal product name	Sotrovimab
Investigational medicinal product code	
Other name	VIR-7831, GSK4182136
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

a) 15 to less than ($<$)40 kilogram (kg): 250 milligram (mg) = 4 milli liter (mL)

b) Greater than or equal to (\geq)40 kilogram (kg): 500 milligram (mg) = 8 milli liter (mL)

Arm title	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)
------------------	--

Arm description:

Participants in the age group 12 to $<$ 18 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1

Arm type	Experimental
Investigational medicinal product name	Sotrovimab
Investigational medicinal product code	
Other name	VIR-7831, GSK4182136
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

a) 15 to less than ($<$)40 kilogram (kg): 250 milligram (mg) = 4 milli liter (mL)

b) Greater than or equal to (\geq)40 kilogram (kg): 500 milligram (mg) = 8 milli liter (mL)

Number of subjects in period 1	Cohort A:Sotrovimab Intravenous (6 to less than [<] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [<] 18 years)
Started	3	5
Completed	1	5
Not completed	2	0
Consent withdrawn by subject	1	-
Lost to follow-up	1	-

Baseline characteristics

Reporting groups

Reporting group title	Cohort A:Sotrovimab Intravenous (6 to less than [<] 12 years)
-----------------------	---

Reporting group description:

Participants in the age group 6 to < 12 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1

Reporting group title	Cohort A:Sotrovimab Intravenous (12 to less than [<] 18 years)
-----------------------	--

Reporting group description:

Participants in the age group 12 to < 18 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1

Reporting group values	Cohort A:Sotrovimab Intravenous (6 to less than [<] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [<] 18 years)	Total
Number of subjects	3	5	8
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	3	0	3
Adolescents (12-17 years)	0	5	5
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Sex: Female, Male			
Units: Participants			
Female	1	4	5
Male	2	1	3
Race/Ethnicity, Customized			
Units: Subjects			
BLACK OR AFRICAN AMERICAN	0	1	1
WHITE	3	4	7
Age, Continuous			
Units: YEARS			
arithmetic mean	9.7	14.2	-
standard deviation	± 0.58	± 1.10	-

End points

End points reporting groups

Reporting group title	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)
Reporting group description: Participants in the age group 6 to $<$ 12 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1	
Reporting group title	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)
Reporting group description: Participants in the age group 12 to $<$ 18 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1	

Primary: Body Weight-Adjusted Serum Clearance (CL) of Sotrovimab

End point title	Body Weight-Adjusted Serum Clearance (CL) of Sotrovimab ^[1]
End point description: Blood samples were collected at indicated timepoints and Pharmacokinetic (PK) analysis was performed. PK parameters were determined by population PK modelling method. The model considered the body weight of each participant to calculate the serum clearance of sotrovimab. The analysis was performed on the PK Principal Stratum Set that included all participants in the PK analysis set who would be able to complete the IV dose.	
End point type	Primary
End point timeframe: Day 1 (End of Infusion), Day 5, 8 and 12, Week 12	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive; hence no statistical analysis to report

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: Liter per day (L/day)				
geometric mean (geometric coefficient of variation)	0.05 (\pm 27.6)	0.10 (\pm 28.5)		

Statistical analyses

No statistical analyses for this end point

Primary: Maximum Observed Concentration (Cmax) Following Administration of Sotrovimab

End point title	Maximum Observed Concentration (Cmax) Following Administration of Sotrovimab ^[2]
-----------------	---

End point description:

Blood samples were collected at indicated timepoints and PK analysis was performed. PK parameters were determined by non-compartmental methods using Phoenix WinNonlin. The log-transformed data is transformed back to the original scale and presented here. The analysis was performed on the PK Principal Stratum Set that included all participants in the PK analysis set who would be able to complete the IV dose. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 (End of Infusion), Day 5, 8 and 12, Week 12

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive; hence no statistical analysis to report

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[3]	5		
Units: microgram per milliliter ($\mu\text{g/mL}$)				
geometric mean (geometric coefficient of variation)	342.96 (\pm 0)	191.67 (\pm 29.45)		

Notes:

[3] - Since only one participant was analyzed, the Geometric Coefficient of Variation was not derived.

Statistical analyses

No statistical analyses for this end point

Primary: Time to Reach Cmax (Tmax) Following Administration of Sotrovimab

End point title	Time to Reach Cmax (Tmax) Following Administration of Sotrovimab ^[4]
-----------------	---

End point description:

Blood samples were collected at indicated timepoints and PK analysis was performed. PK parameters were determined by non-compartmental methods with Phoenix WinNonlin. The analysis was performed on the PK Principal Stratum Set that included all participants in the PK analysis set who would be able to complete the IV dose. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 (End of Infusion), Day 5, 8 and 12, Week 12

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive; hence no statistical analysis to report

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[5]	5		

Units: Day				
median (full range (min-max))	0.000 (0 to 0)	0.003 (0.00 to 0.02)		

Notes:

[5] - Since only one participant was analyzed, the full range (minimum and maximum) were not derived.

Statistical analyses

No statistical analyses for this end point

Primary: Area Under the Serum Concentration-Time Curve from Time Zero to Infinity (AUC[0-inf]) Following Administration of Sotrovimab

End point title	Area Under the Serum Concentration-Time Curve from Time Zero to Infinity (AUC[0-inf]) Following Administration of Sotrovimab ^[6]
-----------------	---

End point description:

Blood samples were collected at indicated timepoints and Pharmacokinetic (PK) analysis was performed. PK parameters were determined by population PK modelling method. The analysis was performed on the PK Principal Stratum Set that included all participants in the PK analysis set who would be able to complete the IV dose.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 (End of Infusion), Day 5, 8 and 12, Week 12

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive; hence no statistical analysis to report

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: Day*microgram per milliliter (day*ug/mL)				
geometric mean (geometric coefficient of variation)	6023.0 (\pm 7.91)	4928.8 (\pm 24.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Terminal Elimination Half-Life (T1/2) Following Administration of Sotrovimab

End point title	Terminal Elimination Half-Life (T1/2) Following Administration of Sotrovimab ^[7]
-----------------	---

End point description:

Blood samples were collected at indicated timepoints and Pharmacokinetic (PK) analysis was performed. PK parameters were determined by population PK modelling method. The analysis was performed on the PK Principal Stratum Set that included all participants in the PK analysis set who would be able to complete the IV dose.

End point type	Primary			
End point timeframe:				
Day 1 (End of Infusion), Day 5, 8 and 12, Week 12				
Notes:				
[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.				
Justification: This endpoint was descriptive; hence no statistical analysis to report				
End point values	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)		
	Reporting group	Reporting group		
	3	5		
	geometric mean (geometric coefficient of variation)	37.5 (\pm 16.1)	43.6 (\pm 22.0)	

Statistical analyses

No statistical analyses for this end point

Primary: Apparent volume of Distribution during Terminal Phase (V_z) Following Administration of Sotrovimab

End point title	Apparent volume of Distribution during Terminal Phase (Vz) Following Administration of Sotrovimab ^[8]			
End point description:				
Blood samples were collected at indicated timepoints and PK analysis was performed. PK parameters were determined by non-compartmental methods with Phoenix WinNonlin. The log-transformed data is transformed back to the original scale and presented here. The analysis was performed on the PK Principal Stratum Set that included all participants in the PK analysis set who would be able to complete the IV dose. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.				
End point type	Primary			
End point timeframe:				
Day 1 (End of Infusion), Day 5, 8 and 12, Week 12				
Notes:				
[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.				
Justification: This endpoint was descriptive; hence no statistical analysis to report				
End point values	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)		
	Reporting group	Reporting group		
	1 ^[9]	5		
	geometric mean (geometric coefficient of variation)	1.42 (\pm 0)	5.49 (\pm 22.08)	

Notes:

[9] - Since only one participant was analyzed, the Geometric Coefficient of Variation was not derived.

Statistical analyses

No statistical analyses for this end point

Primary: Clearance (CL) Following Administration of Sotrovimab

End point title	Clearance (CL) Following Administration of Sotrovimab ^[10]
-----------------	---

End point description:

Blood samples were collected at indicated timepoints and PK analysis was performed. PK parameters were determined by non-compartmental methods with Phoenix WinNonlin. The log-transformed data is transformed back to the original scale and presented here. The analysis was performed on the PK Principal Stratum Set that included all participants in the PK analysis set who would be able to complete the IV dose. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 (End of Infusion), Day 5, 8 and 12, Week 12

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive; hence no statistical analysis to report

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [<] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [<] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[11]	5		
Units: milliliter per day (mL/day)				
geometric mean (geometric coefficient of variation)	42.62 (± 0)	96.58 (± 30.44)		

Notes:

[11] - Since only one participant was analyzed, the Geometric Coefficient of Variation was not derived.

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI) Up to Week 36

End point title	Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI) Up to Week 36 ^[12]
-----------------	---

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death. Protocol defined AESIs were included. The analysis was performed on the Safety Set (Cohort A) that included all

participants who are exposed to study intervention.

End point type	Primary
End point timeframe:	
Up to Week 36	

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive; hence no statistical analysis to report

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [<] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [<] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: Participants				
Participants with AE, n=3,5	1	4		
Participants with SAE, n=3,5	0	0		
Participants with AESI, n=3,5	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Relative Bioavailability (F) Following Administration of Sotrovimab

End point title	Relative Bioavailability (F) Following Administration of Sotrovimab ^[13]
-----------------	---

End point description:

Blood samples were collected at indicated timepoints and PK analysis was performed. PK parameters were determined by non-compartmental methods with Phoenix WinNonlin. Due to early termination of the study, the Intramuscular (IM) administration cohort was not started. The bioavailability assessment was not performed between the Intravenous (IV) and Intramuscular (IM) administration of sotrovimab. Hence there is no data to report.

End point type	Primary
End point timeframe:	
Day 1 (End of Infusion), Day 5, 8 and 12, Week 12	

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive; hence no statistical analysis to report

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [<] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [<] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[14]	0 ^[15]		
Units: Percentage				
geometric mean (confidence interval 95%)	(to)	(to)		

Notes:

[14] - The assessment was not performed and there is no data to report.

[15] - The assessment was not performed and there is no data to report.

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI)

End point title	Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI) ^[16]
-----------------	---

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death. Protocol defined AESIs were included. The analysis was performed on the Safety Set (Cohort A) that included all participants who are exposed to study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Up to Day 29

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive; hence no statistical analysis to report

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: Participants				
Participants with AE, n=3,5	1	2		
Participants with SAE, n=3,5	0	0		
Participants with AESI, n=3,5	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Progression of COVID-19 through Day 29

End point title	Number of Participants with Progression of COVID-19 through Day 29
-----------------	--

End point description:

Progression of COVID-19 is defined as need for attended medical visit (including the visit to a hospital emergency room for management of illness or hospitalization for acute management of illness) or escalation to higher level of medical care or death. The analysis was performed on the Safety Set

(Cohort A) that included all participants who are exposed to study intervention.

End point type	Secondary
End point timeframe:	
Up to Day 29	

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [<] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [<] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: Count of Participants	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Viral Load in Nasal Secretions Measured by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR)

End point title	Change from Baseline in Viral Load in Nasal Secretions Measured by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR)
-----------------	---

End point description:

The viral load change from baseline in nasal secretions was measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) at Day 5, Day 8, and Day 11. The analysis was performed on the Safety Set (Cohort A) that included all participants who are exposed to study intervention. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.

End point type	Secondary
End point timeframe:	
Baseline (Day 1), at Day 5, Day 8 and Day 11	

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [<] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [<] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	5		
Units: log10 copies per milliliter				
arithmetic mean (standard deviation)				
Baseline (Day 1), n=2,5	5.085 (± 0.2475)	4.712 (± 1.0668)		
Day 5, n=2,5	-1.270 (± 2.6304)	-2.160 (± 1.4053)		

Day 8, n=2,5	-2.640 (± 0.6930)	-2.398 (± 1.6272)		
Day 11, n=2,5	-3.305 (± 0.2475)	-2.870 (± 1.1430)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Development of Severe and/or Critical Respiratory COVID-19 through Day 29

End point title	Number of Participants with Development of Severe and/or Critical Respiratory COVID-19 through Day 29
-----------------	---

End point description:

Severe and/or critical respiratory COVID-19 as manifested by requirement for supplemental oxygen through Day 29. For participants who required oxygen or respiratory support for premorbid conditions, disease progression was defined as any sustained (greater than [$>$]24 hours) increase in the level or method of oxygen support required. The analysis was performed on the Virology Set (Cohort A) that included all participants who are exposed to study treatment and have a quantifiable SARS-CoV-2 viral load measurement at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 29

End point values	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: Count of Participants	0	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Upto Week 36

Adverse event reporting additional description:

Safety Set comprised of all participants who are exposed to study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

Reporting groups

Reporting group title	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)
-----------------------	--

Reporting group description:

Participants in the age group 12 to $<$ 18 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1

Reporting group title	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)
-----------------------	---

Reporting group description:

Participants in the age group 6 to $<$ 12 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1

Serious adverse events	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort A:Sotrovimab Intravenous (12 to less than [$<$] 18 years)	Cohort A:Sotrovimab Intravenous (6 to less than [$<$] 12 years)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 5 (80.00%)	1 / 3 (33.33%)	
Investigations			
Alanine aminotransferase increased			
alternative dictionary used: v26.0 26.0			

subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Aspartate aminotransferase increased			
alternative dictionary used: v26.0 26.0			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Blood creatinine increased			
alternative dictionary used: v26.0 26.0			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Haematocrit increased			
alternative dictionary used: v26.0 26.0			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Haemoglobin increased			
alternative dictionary used: v26.0 26.0			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Neutrophil count decreased			
alternative dictionary used: v26.0 26.0			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Platelet count decreased			
alternative dictionary used: v26.0 26.0			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
White blood cell count decreased			
alternative dictionary used: v26.0 26.0			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
Contusion			
alternative dictionary used: v26.0 26.0			

subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	
Congenital, familial and genetic disorders Hypoplastic left heart syndrome alternative dictionary used: v26.0 26.0 subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	
Immune system disorders Graft versus host disease alternative dictionary used: v26.0 26.0 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 3 (33.33%) 1	
Hepatobiliary disorders Hepatic fibrosis alternative dictionary used: v26.0 26.0 subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	
Infections and infestations Gastroenteritis viral alternative dictionary used: v26.0 26.0 subjects affected / exposed occurrences (all) Polyomavirus viraemia alternative dictionary used: v26.0 26.0 subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1 0 / 5 (0.00%) 0	0 / 3 (0.00%) 0 1 / 3 (33.33%) 1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 October 2021	The rationale for this amendment is to update the dosing scheme to use weight-based dosing; to make intramuscular (IM) dosing contingent on confirmation of the efficacy of IM dosing in adults; to include occurrence of multisystem inflammatory syndrome in children (MIS C) as an objective per European Medicines Agency Pediatric Committee request and to align blood sample collection volumes in participants <2 years to be within acceptable limits set out by the National Institute of Health (NIH) directives.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to the early termination of the study and the small number of participants (N=8), both the non-compartmental analysis and sotrovimab Population PK model were used to report the primary endpoints.

Notes: